UR
BMY.RT

USCA RIA’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

USCA RIA’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-12,802
Closed -$9K – 564
2020
Q4 		$9K Sell
12,802
-23
-0.2% -$49 ﹤0.01% 488
2020
Q3 		$29K Sell
12,825
-113
-0.9% -$323 ﹤0.01% 460
2020
Q2 		$46K Sell
12,938
-1,285
-9% -$4.64K ﹤0.01% 440
2020
Q1 		$54K Sell
14,223
-2,350
-14% -$7.74K 0.01% 397
2019
Q4 		$50K Buy
+16,573
New +$43.1K ﹤0.01% 459

Other funds holding BMY.RT

JCI
Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
BC
Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return
TNB
Thomasville National Bank Thomasville, Georgia $1.82B AUM
WAM
Westport Asset Management Southport, Connecticut $226M AUM 16.76% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.67B AUM 28.26% 1-Year Est. Return

USCA RIA's BMY.RT Position: Q1 2021 in Review

USCA RIA sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 12,802 shares — an estimated $9K sold.

USCA RIA first reported a position in BMY.RT in Q4 2019 and held it in 5 quarters. The position peaked at $54K in Q1 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

  • USCA RIA reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
  • USCA RIA sold 12,802 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $9K.
  • USCA RIA first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 5 quarters.
  • USCA RIA's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $54K in Q1 2020.
  • 12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on USCA RIA's 13F filing for Q1 2021, filed 27 Apr 2021.